Format

Send to

Choose Destination
Expert Rev Anticancer Ther. 2006 Jun;6(6):905-9.

Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma.

Author information

1
Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, 4805 NE Glisan Street #5F40, Portland, Oregon 97213, USA. brendan.curti@providence.org

Abstract

Interleukin (IL)-21 is a class I cytokine with sequence homology to the IL-2 cytokine superfamily. IL-21 signals through a heterodimer of a unique IL-21 receptor and the common gamma-chain cytokine receptor. Preclinical murine models suggested strong antitumor activity of IL-21 in renal cell carcinoma, melanoma and other tumor models. IL-21 antitumor activity was superior to IL-2 in these tumor models. A Phase I clinical trial of IL-21 in humans with metastatic renal cell carcinoma or melanoma began in May 2004. Clinical regressions were observed in renal cell carcinoma. Preliminary immunological and clinical findings of patients receiving IL-21 will be reviewed.

PMID:
16761934
DOI:
10.1586/14737140.6.6.905
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center